X4 Pharmaceuticals, Inc. (XFOR)
NASDAQ: XFOR · Real-Time Price · USD
4.310
+0.170 (4.11%)
At close: May 29, 2026, 4:00 PM EDT
4.400
+0.090 (2.09%)
After-hours: May 29, 2026, 5:22 PM EDT
X4 Pharmaceuticals Revenue
X4 Pharmaceuticals had revenue of $2.71M in the quarter ending March 31, 2026, a decrease of -90.60%. This brings the company's revenue in the last twelve months to $9.01M, down -71.26% year-over-year. In the year 2025, X4 Pharmaceuticals had annual revenue of $35.11M with 1,273.21% growth.
Revenue (ttm)
$9.01M
Revenue Growth
-71.26%
P/S Ratio
43.63
Revenue / Employee
$200,311
Employees
45
Market Cap
406.52M
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2025 | 35.11M | 32.56M | 1,273.21% |
| Dec 31, 2024 | 2.56M | - | - |
| Dec 31, 2023 | - | - | - |
| Dec 31, 2022 | - | - | - |
| Dec 31, 2021 | - | - | - |
| Dec 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| Puma Biotechnology | 227.18M |
| Vanda Pharmaceuticals | 217.78M |
| Enanta Pharmaceuticals | 69.21M |
| Verastem | 49.59M |
| OmniAb | 28.94M |
| Artiva Biotherapeutics | 251.00K |
| InflaRx | 33.82K |
| Lyell Immunopharma | 31.00K |
XFOR News
- 2 days ago - X4 Pharmaceuticals to Present at the 2026 Jefferies Global Healthcare Conference - GlobeNewsWire
- 22 days ago - X4 Pharmaceuticals reports Q1 EPS (16c), consensus (20c) - TheFly
- 22 days ago - X4 Pharmaceuticals files $300M mixed securities shelf - TheFly
- 23 days ago - X4 Pharmaceuticals Registration statement: Registration filing - Filings
- 23 days ago - X4 Pharmaceuticals Reports First Quarter 2026 Financial Results and Provides Corporate Update - GlobeNewsWire
- 23 days ago - X4 Pharmaceuticals Quarterly report: Q1 2026 - Filings
- 23 days ago - X4 Pharmaceuticals Earnings release: Q1 2026 - Filings
- 4 weeks ago - X4 Pharmaceuticals announces EC approval of Xolremdi - TheFly